Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Susan Coultas PhD Appointed Chief Clinical Officer of Clearside Biomedical

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

In this role, Susan Coultas PhD will serve as a member of the executive team and has overall responsibility for planning the initiation and execution of Clearside’s clinical trials, including oversight of all clinical development operations.

“We are very excited to have Susan join our team,” said George Lasezkay, Pharm.D., J.D., Clearside Biomedical President and Chief Executive Officer. “With her broad experience in clinical development at multiple leading ophthalmic companies, she will make significant contributions to Clearside’s vision, strategy, and operational effectiveness. Her expertise in advancing a therapy from the initial clinical development stages through approval for commercialization will be a valuable asset as we continue to progress our lead candidate, CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD). Dr. Thomas Ciulla, our Chief Medical Officer and Chief Development Officer, will continue his current responsibilities for clinical trial design and overall product pipeline strategy and development. Tom will work closely with Susan regarding the implementation and analysis of our clinical pipeline programs.”

“I am pleased to join a dedicated team focused on developing a new generation of impactful treatments for retinal diseases utilizing a proven approach with our suprachoroidal space injection platform,” said Susan L. Coultas, Ph.D., Chief Clinical Officer. “I look forward to working with the executive team and supporting our clinical programs to realize the broad potential of our pipeline to benefit patients with sight-threatening eye diseases.”

Susan Coultas PhD brings 35 years of experience in clinical development in the biopharmaceutical industry. Most recently, she served as Senior Vice President of Clinical Development at Kala Pharmaceuticals, where she was responsible for the planning and execution of its clinical programs, resulting in two new drug application filings and product approvals.

Susan Coultas PhD has worked with multiple ophthalmic companies, both internally and as a consultant, including Alcon Laboratories, Inc., CibaVision Ophthalmics, Sucampo Pharmaceuticals, and Bausch+Lomb, Inc. Earlier in her career, as owner of InfoQuest Clinical Network, Inc., Dr. Coultas successfully identified, developed, and led a large network of clinical research professionals that managed numerous clinical trials in multiple systemic and ophthalmic therapeutic areas.

Coultas earned a Ph.D. in Public Health, Epidemiology, from Walden University, a M.S. in Biology from University of North Texas, and a B.S. in Biology from Texas Wesleyan University.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine